| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2014 | 3,4-Dihydroxytoluene, a metabolite of rutin, inhibits inflammatory responses in lipopolysaccharide-activated macrophages by reducing the activation of NF-κB signaling | KANG-YI SU ; Yu C.Y.; Chen Y.-P.; Hua K.-F.; Chen Y.-L.S. | BMC Complementary and Alternative Medicine | 45 | 43 | |
| 2020 | ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients | Chang, Gee-Chen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen | Scientific reports | 20 | 18 | |
| 2018 | Application of single nucleotide extension and MALDI-TOF mass spectrometry in proofreading and DNA repair assay | KANG-YI SU ; Lai H.-M.; Goodman S.D.; Hu W.-Y.; WERN-CHERNG CHENG ; LIANG-IN LIN ; YA-CHIEN YANG ; WOEI-HORNG FANG | DNA Repair | 5 | 4 | |
| 2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 40 | 38 | |
| 2018 | The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Chen, Kun-Chieh; Hsu, Chia-Hung; KANG-YI SU ; Chen, Jeremy J W; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang, Tsung-Ying; Chang, Gee-Chen | Cancer Research and Treatment | 40 | 38 | |
| 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 13 | 13 | |
| 2018 | Characteristics and Predictive Value of PD-L1 Status in Real-World NonSmall Cell Lung Cancer Patients | Tseng J.-S.; Yang T.-Y.; Wu C.-Y.; Ku W.-H.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Journal of Immunotherapy | 21 | 21 | |
| 2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 5 | 5 | |
| 2018 | Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer | MONG-WEI LIN ; KANG-YI SU ; Su T.-J.; Chang C.-C.; Lin J.-W.; Lee Y.-H.; SUNG-LIANG YU ; JIN-SHING CHEN ; MIN-SHU HSIEH | Lung Cancer | 36 | 32 | |
| 2011 | Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations | Yuan S.; SUNG-LIANG YU ; Chen H.-Y.; Hsu Y.-C.; KANG-YI SU ; HUEI-WEN CHEN ; Chen C.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; YIH-LEONG CHANG ; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; PAN-CHYR YANG | Journal of Clinical Oncology | 26 | 24 | |
| 2016 | Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis | Chen L.-Y.; Molina-Vila M.A ; SHENG-YUAN RUAN ; KANG-YI SU ; WEI-YU LIAO ; KAI-LUN YU ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG ; Rosell R.; PAN-CHYR YANG | Lung Cancer | 53 | 51 | |
| 2020 | Copy Number Alterations of Depressed Colorectal Neoplasm Predict the Survival and Response to Oxaliplatin in Proximal Colon Cancer | LI-CHUN CHANG ; HAN-MO CHIU ; Ho, Bing-Ching; Chen, Min-Hsuan; Hsu, Yin-Chen; Chiu, Wei-Tzu; KANG-YI SU ; CHIA-TUNG SHUN ; JIN-TUNG LIANG ; SUNG-LIANG YU ; MING-SHIANG WU | Cancers | 5 | 5 | |
| 2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
| 2006 | Decreased expressions of hepsin in human hepatocellular carcinomas | CHIEN-HUNG CHEN ; KANG-YI SU ; Tao M.-H.; SHU-WHA LIN ; Su Y.-H.; Tsai Y.-C.; Cheng K.-C.; YUNG-MING JENG ; JIN-CHUAN SHEU | Liver International | 16 | 18 | |
| 2016 | Dichloromethane extracts of propolis protect cell from oxygenglucose deprivation-induced oxidative stress via reducing apoptosis | Sun L.-P.; Xu X.; Hwang H.-H.; Wang X.; KANG-YI SU ; Chen Y.-L.S. | Food and Nutrition Research | 12 | 10 | |
| 2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 2 | 2 | |
| 2018 | DNA polymerase I proofreading exonuclease activity is required for endonuclease V repair pathway both in vitro and in vivo | KANG-YI SU ; LIANG-IN LIN ; Goodman S.D.; Yen R.-S.; Wu C.-Y.; Chang W.-C.; YA-CHIEN YANG ; WERN-CHERNG CHENG ; WOEI-HORNG FANG | DNA Repair | 8 | 8 | |
| 2015 | Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma | Tseng, Jeng-Sen; Yang, Tsung-Ying; Tsai, Chi-Ren; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Chen, Jeremy J. W.; MONG-HSUN TSAI | Journal of Thoracic Oncology | 59 | 59 | |
| 2015 | EGFR mutation and lobar location of lung adenocarcinoma | Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO ; Hsia T.-C.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Yang T.-Y.; Chang G.-C. | Carcinogenesis | 9 | 11 | |
| 2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng, Chien-Hua; CHUN-JU CHIANG ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; Wang, Chih-Liang; Chen, Chih-Yi; Yen, Sang-Hue; Tsai, Chun-Ming; Huang, Ming-Shyan; CHAO-CHI HO ; CHONG-JEN YU ; Tsai, Ying-Huang; JIN-SHING CHEN ; Chou, Teh-Ying; Tsai, Ming-Hsun; Chen, Hsuan-Yu; KANG-YI SU ; Chen, Jeremy J. W.; HUEI-WEN CHEN ; SUNG-LIANG YU ; Liu, Tsang-Wu; MONG-HSUN TSAI | Oncotarget | 46 | 33 | |
